Horizon Pharma plc (HZNP): $2.52 million was the positive money flow into the stock on Friday and the up/down ratio of ticks was also in favor of the bulls at 1.51. The value of trades done on upticks was $7.5 million, whereas, trades done on downticks were valued at $4.98 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $2.29 million worth stocks on upticks, which is a bullish indication. The downticks accounted only for $0.37 million worth of block trades showing a lack of interest among the large traders to sell the stock down. The up/down ratio of 6.17 was strongly in favor of the bulls. The money flow in block trades was $1.92 million. Horizon Pharma plc (HZNP) fell $0.32 traded at $18.3, a change of -1.72% over the previous day. The stock is -5.82% for the week.
The company Insiders own 2.1% of Horizon Pharma plc shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -7.4% . Institutional Investors own 87.68% of Horizon Pharma plc shares. During last six month period, the net percent change held by insiders has seen a change of -7.4%.
In a related news, Sherman Jeffrey W, officer (EVP and Chief Medical Officer) of Horizon Pharma Plc, unloaded 2,900 shares at an average price of $20 on August 2, 2016. The total amount of the transaction was worth $58,000, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Horizon Pharma plc (NASDAQ:HZNP): stock was range-bound between the intraday low of $17.68 and the intraday high of $18.96 after having opened at $18.71 on Fridays session. The stock finally closed in the red at $18.71, a loss of -4.19%. The stock remained in the red for the whole trading day. The total traded volume was 4,359,448 shares. The stock failed to cross $18.96 in Fridays trading. The stocks closing price on Thursday was $18.62.
Horizon Pharma plc (HZNP) : During the past 4 weeks, traders have been relatively bearish on Horizon Pharma plc (HZNP), hence the stock is down -11.13% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -8.64% relative to the S&P 500. The 4-week change in the price of the stock is -11.24% and the stock has fallen -8.18% in the past 1 week.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.